文献速递浆细胞疾病造血干细胞移植与细胞治疗

移植时肾功能不全的多发性骨髓瘤患者自体造血干细胞移植后低非复发死亡率和良好的血液学及肾脏反应:一项法国法语区骨髓移植与细胞治疗学会的前瞻性观察性研究

Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational study.
PubMed 文献 · Br J Haematol · 2023-11-12

这项多中心(16个SFGM-TC中心)前瞻性队列研究纳入50例移植时肌酐清除率<40 mL/min的新诊断多发性骨髓瘤患者,接受推荐剂量美法仑140 mg/m²后行自体造血干细胞移植。第100天非复发死亡1例,中性粒细胞植入中位12天、血小板植入中位13天,69%患者血液学反应改善,2年总生存84%、无进展生存70%、累积复发率20%,59%患者肾脏反应改善。作者认为移植时肾功能不全的骨髓瘤患者行自体移植安全有效。

要点

  • 50例移植时肌酐清除率<40 mL/min的多发性骨髓瘤患者接受美法仑140 mg/m²及自体移植,第100天非复发死亡1例。
  • 中性粒细胞植入中位12天,血小板植入中位13天,69%患者血液学反应改善。
  • 2年总生存84%、无进展生存70%、累积复发率20%,59%患者肾脏反应改善。

核心结论

  • 作者认为,移植时存在肾功能不全的多发性骨髓瘤患者行自体造血干细胞移植是安全且有效的。

研究设计与样本

  • 多中心(16个SFGM-TC中心)前瞻性观察性队列研究,纳入50例移植时血清肌酐清除率<40 mL/min的新诊断多发性骨髓瘤患者。
  • 患者接受推荐剂量美法仑140 mg/m²后行自体造血干细胞移植,主要终点为第100天非复发死亡率。

主要发现

  • 移植后前100天内发生1例死亡。
  • 中性粒细胞植入中位时间为12天,血小板植入中位时间为13天。
  • 69%的患者血液学反应改善,最佳反应包括:部分缓解(PR)至非常好的部分缓解(VGPR)占10%,PR至完全缓解(CR)/严格完全缓解(sCR)占16%,VGPR至CR/sCR占39%,CR至sCR占2%。
  • 2年时总生存率为84%,无进展生存率为70%,累积复发率为20%。
  • 59%的患者肾脏反应改善,移植后最佳肾脏反应为微小反应占9%、部分反应占2%、完全反应占48%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-dose melphalan followed by autologous haematopoietic stem cell transplantation is widely used in newly diagnosed multiple myeloma (MM) patients as upfront therapy. However, the safety and efficacy of transplantation in patients with renal insufficiency (RI) are controversial. We followed a multicentre (16 SFGM-TC centres) prospective cohort of 50 newly diagnosed MM patients with a serum creatinine clearance of <40 mL/min at transplantation. Patients received a recommended dose of melphalan of 140 mg/m2. The primary end-point was the non-relapse mortality at Day 100. One death occurred during the first 100 days post-transplant. The median time to neutrophil engraftment was 12 days and to platelet engraftment was 13 days. The haematological response improved in 69% of patients, with best responses from partial response (PR) to very good partial response (VGPR) (10%), from PR to complete response (CR)/stringent complete response (sCR) (16%), from VGPR to CR/sCR (39%) and from CR to sCR (2%). At 2 years, the overall survival was 84%, the progression-free survival was 70% and the cumulative incidence of relapse was 20%. The renal response improved in 59% of patients, with the best renal responses post-transplant being minimal (9%), partial (2%) and complete (48%). Autologous transplantation was safe and effective in myeloma patients with RI at transplant.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Garderet L, Ouldjeriouat H, Bekadja MA, et al. Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational study. Br J Haematol. 2023. PMID: 37953476. doi:10.1111/bjh.19163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。